Clozapine for Post-traumatic Stress Disorder: Redefining Treatment Resistance in Soldiers without Psychosis Authors: Roshan Monaragala, Miyuru Chandradasa, KALA Kuruppuarachchi Published: 2026 ABSTRACT AbstractPost-traumatic stress disorder (PTSD) often follows a chronic trajectory, with many patients failing to respond to first-line psychotherapy and SSRIs/SNRIs. This case series explores clozapine for treatment-resistant PTSD (TR-PTSD) without psychosis. Seven soldiers showed improved function and reduced aggression at doses of 125–300 mg, suggesting that clozapine warrants further investigation.Keywords: Antipsychotic agents, clozapine, military personnel, stress disorders, post-traumatic, treatment resistance Post-traumatic stress disorder (PTSD), characterized by three core symptoms (i.e., re-experiencing the trauma in the present, deliberate avoidance of things reminiscent of the trauma, and persistent perceptions of heightened current threat), is associated with severe stressors such as combat exposure. It is a serious psychiatric disorder affecting 3.9% globally, reducing the quality of life, and affecting multiple psychosocial domains.1,2 Moreover, PTSD, despite receiving treatment, is shown to have a chronic trajectory, particularly among military veterans, which leads to lasting implications in occupational and social functioning, along with physical and mental health complications.1,2 Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are recommended as first-line treatment for PTSD. 3 However, for first-line treatment, as few as 20%–30% achieve full remission, and 30%–40% experience partial response, and augmentation strategies with other types of medications and psychological approaches have yielded mixed results, underscoring the importance of treatment-resistant PTSD (TR-PTSD). 3 Failure to respond to one or more evidence-basedfirst-line treatments (including trauma-focused psychotherapy) despite adequate dosage and duration is considered TR-PTSD.1,2 To date, there is no empirically validated treatment algorithm for TR-PTSD, and we propose clozapine as a treatment option, highlighting our experience with it. Further, there are no previous studies on clozapine use for TR-PTSD in the absence of psychosis. Case Series A consultant psychiatrist clinically diagnosed all seven cases shown in Table 1 according to the ICD-11 criteria. Notably, all met the criterion D (i.e., Negative alterations in cognitions and mood associated with the traumatic events), which is a key feature to diagnose complex PTSD (CPTSD). It is noteworthy that none of the cases exhibited psychotic symptoms, and many had at least one co-morbidity. In addition to the first-line treatment options, second-generation antipsychotics (quetiapine) and other antidepressants (mirtazapine and amitriptyline) were instituted at the maximum tolerated doses, for approximately 12 months, but without any meaningful effect. Prolonged Exposure Therapy (Case 1) and Trauma-Focused Cognitive Behavioral Therapy (Case 3) were instituted for two cases without significant therapeutic benefit. In contrast, in the remaining cases, these were not applied due to severe emotional and/or behavioral disturbance that affected their occupational and social functioning (Table 1). Before clozapine initiation, the cases were selected to meet the proposed criteria for TR-PTSD (i.e., symptoms persisting with functional impairment and emotional dysregulation for over 12 months despite standard treatments, including the failure of psychotherapeutic measures).1,2 Table 1.Description of Soldiers with Treatment-resistant Post-traumatic Stress Disorder Treated with Clozapine.CasesAge at InjuryTrauma & Index InjuryKey Clinical FeaturesComorbiditiesPrior 12-month TreatmentInstitution of ClozapineMaximum Tolerated DoseResponse Within 3 MonthsIssues Case 1 20 yearsMortar blastRight-sided blindnessSleep disturbance due to nightmares, night-terrors, and somnambulanceAggression, emotional numbing, and thrice attempted suicidePanic disorderNicotine dependenceProlonged Exposure TherapyFluoxetine(60 mg)Duloxetine(60 mg)Quetiapine(400 mg)200 mgSymptom remission.Resumed duties.Interpersonal relationships improved.Minor tolerable side effects Case 2 21 yearsBomb explosionShrapnel injury to the abdomenSleep disturbance due to nightmaresIntrusive and distressing images. Suspicion of superiors, and the spouse’s fidelityDissociative symptoms (seizures and paraplegia)AggressionMixed anxiety and depressive disorder.Nicotine dependence and harmful use of cannabisFluoxetine(80 mg)Mirtazapine(45 mg)Quetiapine(200 mg)250 mgMost symptoms improved with minor residual difficulties (Occasional nightmares and distressing thoughts)Resumed duties.Interpersonal relationships improved.No notable complaints Case 3 20 yearsArtillery Shell BlastMild cervical injurySleep disturbance due to nightmaresDistressing images and thoughts about the traumaEmotional numbingSuspicion about others (overvalued idea)ReclusivenessMultiple somatic complaints and analgesic dependenceTwice attempted suicideRecurrent depressive disorderTrauma-focused Cognitive Behavioral TherapyFluoxetine(40 mg)Duloxetine(60 mg)Mirtazapine(30 mg)Quetiapine(125 mg)125 mg(Fluoxetine 20 mg was re-added)Condition improved with fewer re-experiencing phenomenaResumed duties.Family interactions improved.No notable complaints Case 4 24 yearsExposure and witnessing the deaths of comrades in an ambushSleep disturbance due to nightmaresIntrusive thoughts and images about the ambushSensitive to loud soundsSuspicion about others (overvalued idea)Aggressive outburstsAttempts of deliberate self-harmReclusivenessRecurrent depressive disorderHarmful use of alcoholFluoxetine(60 mg)Mirtazapine(45 mg)Duloxetine(60 mg)Amitriptyline (125 mg)Quetiapine(200 mg)250 mg(Fluoxetine 20 mg was re-added)Condition improved with minor residual symptoms (sensitivity to sounds and occasional nightmares)Interpersonal relationships improved, and he resumed duties.Minor tolerable side effects, such as sedation Case 5 21 yearsMortar blast followed by the death of comradesMild shrapnel injury to the head and neckSleep disturbance due to nightmaresDistressing, intrusive imagesDissociative symptoms (seizures, hemiparesis, and muteness)Reclusiveness, querulousness, and irritabilityAttempted suicide by hanging and overdosingPanic disorderFluoxetine(60 mg)Mirtazapine(45 mg)Doxepin(100 mg)Quetiapine(300 mg)200 mgCondition improved with a lesser intensity of nightmares and distressing images.Reclusive and querulous behavior improved.Marked weight loss and clozapine was discontinued(the PTSD symptoms returned) Case 6 Many injuries during the early twentiesEncountered explosions and small firearmsShrapnel injuries to the chest and abdomenSleep disturbance due to nightmares and night-terrorsDistressing images and thoughtsFlashbacksHypervigilanceSuspicion about wife’s fidelity (overvalued idea)Parkinsonism (Unrelated to PTSD)Sertraline(150 mg)Clomipramine (150 mg)Duloxetine(60 mg)Mirtazapine(45 mg)Quetiapine(250 mg)150 mgNightmares, flashbacks, and hypervigilance were reduced in frequency and intensity.Increased drowsiness, constipation, nocturia, and hyper salivationClozapine was discontinued (the PTSD symptoms returned) Case 7 22 yearsAnti-personnel mine blastTraumatic amputation of the right legSleep disturbance due to nightmaresIntrusive, distressing images and thoughtsEmotional numbnessReclusivenessAggressive outburstsMultiple attempts of deliberate self-harmAttempted suicide oncePanic disorderNicotine dependenceSupportive psychotherapyFluoxetine(60 mg)Duloxetine(60 mg)Mirtazapine(45 mg)Quetiapine(300 mg)300 mgSleep improved with fewer nightmaresIrritability and explosive behavior reduced.Increased drowsiness, frequent falls, and tachycardia Clozapine was discontinued (the PTSD symptoms returned) Description of Soldiers with Treatment-resistant Post-traumatic Stress Disorder Treated with Clozapine. All responded to clozapine at daily doses between 125 and 300 mg. Although full remission was not achieved (except in Case 1), they became functional (i.e., resumed their occupational and family roles) and tolerated the residual symptoms. Moreover, the suicidal and aggressive tendencies were reduced, and interpersonal relationships improved. If clozapine was discontinued (Cases 5, 6, and 7), it was mainly due to intolerable side effects (i.e., undue drowsiness, marked weight loss, nocturia, and constipation). In 4 of 7 cases (Cases 1–4), they continue to function well on clozapine without significant adverse effects at present. Discussion Clozapine is a unique atypical antipsychotic because of its numerous receptor affinities, including serotonin (5-HT1C, 5-HT2), adrenergic (α1), muscarinic (M), histamine (H1), and dopamine (D1-D5) receptors. 4 Furthermore, it is demonstrated to be effective for psychiatric conditions resistant to conventional treatments (e.g., in schizophrenia), and in reducing suicidality, aggression, depression, and substance use. 5 There are empirically valid reasons to rationalize clozapine as a treatment option for TR-PTSD. Investigations suggest that PTSD symptoms arise from dysregulation of serotonergic, dopaminergic, and noradrenergic neurotransmitter systems, as well as dysfunction of the hypothalamic–pituitary–adrenal axis; given its receptor affinity profile, clozapine may therefore alleviate these symptoms by modulating dopaminergic and serotonergic pathways and antagonizing α1-adrenergic receptors. 6 Sleep disturbance independently exacerbates daytime symptom severity, giving rise to treatment refractoriness in PTSD, and herein, the sedative properties of clozapine mediated by its antihistaminergic action could ameliorate the symptoms of PTSD.1,3 Comorbidities of PTSD (depression, anxiety, psychotic symptoms, and substance use disorders) are implicated in treatment resistance, and thereby, full remission requires concurrent improvement in both PTSD and comorbid symptoms. 7 Hence, given its established therapeutic versatility in schizophrenia with comorbidities, clozapine can be viewed as a rational treatment option for TR-PTSD. 8 In addition, complex PTSD, a subtype characterized by disturbances in affect regulation, self-concept, and interpersonal functioning, is shown to be refractory to standard treatment. Therefore, arguably, considering the mood-stabilizing, antidepressant, and calming effects, clozapine can be considered a rational therapeutic alternative.8,9 Compared to non-combat-related trauma, combat-related trauma is observed to incur a severe and chronic form of PTSD along with comorbidities, and often at a higher risk of developing TR-PTSD. 10 These findings converge with our hindsight experience, and hence, treatment of combat-related PTSD should be viewed differently, justifying our institution of clozapine. Most side effects of clozapine are benign and manageable; nevertheless, they are a major reason attributed to poor drug compliance, which was so among three of our patients (Table 1). 4 However, it is noteworthy that the prevalence of serious negative adverse effects of clozapine, including agranulocytosis and cardiac complications, has been overestimated, leading to the false impression that clozapine is dangerous. 11 In fact, a prospective 11-year study on patients with treatment-resistant schizophrenia demonstrated that the risk of premature mortality is comparatively lower in those on clozapine than in those on other antipsychotics and not on medication. 12 The four cases that showed a significant improvement, and the other three, though discontinued due to intolerable side effects (non-fatal), displayed symptom reduction with clozapine, posit the therapeutic benefit of clozapine in TR-PTSD. Thereby, like treatment-resistant schizophrenia, we contend that PTSD elevates mortality risks (due to suicidal tendencies and cardiac complications) and impairs quality of life. 13 The benefits of clozapine treatment in TR-PTSD most likely outweigh its intrinsic risks in carefully selected cases with severe functional decline. Three patients (Cases 1, 2, and 7) had comorbid nicotine dependence and required higher therapeutic doses of clozapine (200–300 mg), which likely reflects the known inductive effect of tobacco smoking on CYP1A2 metabolism, a factor clinicians must closely evaluate during titration. 14 This is the first case series in the published literature to examine the clinical use of clozapine in a group of young soldiers with severe, combat-related treatment-resistant PTSD (TR-PTSD) who had no diagnosable psychotic symptoms. We emphasize the lack of a control group, the variable treatment responses, the lack of long-term post-discontinuation follow-up data to determine optimal treatment duration, and the low rate of concurrent trauma-focused psychotherapy due to severe initial behavioral disturbances and structural service constraints. The findings of this study are insufficient to determine the optimal duration of clozapine treatment in TR-PTSD due to variable responses; hence, a prospective study is warranted. Conclusion Due to the mounting societal and combat violence globally, the prevalence of PTSD would be higher in the future, and more robust and effective methods should be developed. As we have shown, clozapine is a promising alternative for carefully selected cases with significant functional impairment that should be empirically tested in future randomized controlled trials. Supplemental Material Supplemental material for this article is available online.